Skip to main content
. 2024 May 29;44(5):BSR20230667. doi: 10.1042/BSR20230667

Figure 3. Cell survival in GBM spheroids after TMZ treatment.

Figure 3

(A) Survival Fraction (SF) of U251MG WTE and TLS Polκ KO cells disaggregated from 3D tumor spheroids treated with TMZ and respective controls until Day 5. In the assay, colonies formed after 10 days of 3000 cells disaggregated from 3D tumor spheroids were analyzed. (B) Photomicrograph of the colonies formed after 10 days of disaggregated cells from 3D tumor spheroids. All data were represented as means ± standard deviation (X ± SD) from six spheroids (n=6) per well and three independent biological experiments (n=3). *Values statistically different from the U251MG WTE cells at the point (date) (**P<0.01, ***P<0.001, ****P<0.0001; Two-way ANOVA followed by Bonferroni post-test). PC: Positive Control (Cisplatin 100 μM); SC: Solvent Control (1% DMSO); TMZ: Temozolomide.